NEWS AND MEDIA
Recent News
Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines Expected to Air Sunday, February 24, 2019
In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full Prescribing Information and Box Warning here)1 based on a robust set of clinical trials, which the FDA dubbed at the time the “gold…
Patients Who Receive Information About the Importance of Safe Disposal Are Three Times More Likely to Dispose of Unused Prescription Opioid Medications
Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute to the safe disposal of opioids STAMFORD, Conn., February 20, 2019 — Purdue Pharma L.P. today announced the publication of a survey study that found…
Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment
Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones STAMFORD, Conn. and BOSTON – Jan 28, 2019 — Purdue Pharma L.P.…
Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – Purdue Pharma L.P. and Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization…
Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that…
Purdue Pharma Urges Accuracy in Communications on Abuse-Deterrent Formulations of Opioids
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is deeply concerned…
Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual ConferenceResults Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. –…
Purdue Pharma L.P. to Present Data from Three Research Studies at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual ConferenceStudies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September 6, 2018 – Purdue…
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive, Over-the-Counter, Life-Saving Naloxone in the United States
STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced that Purdue is providing a $3.42 million grant to Harm Reduction Therapeutics to advance the development of its low-cost,…
Prescription Drug Safety Curriculum Increased Student Knowledge by 49 Percent in its Inaugural Academic Year
Purdue Expands Established Commitment to Include a Statewide Education Program in Collaboration with EVERFI and Connecticut Prevention Network for the 2018-2019 Academic Year STAMFORD, Conn., August 15, 2018 — Purdue Pharma L.P. today announced that, through its…